Teva Pharmaceutical Industries (NYSE: TEVA) Announces 2024 Full Year and Fourth Quarter Financial Results

On January 29, 2025, Teva Pharmaceutical Industries Ltd. released a press statement unveiling its financial outcomes for the period concluding on December 31, 2024. The results were disclosed through an official press release, which has been made available as Exhibit 99.1 in the Form 8-K filing submitted. The information encompassed within this announcement is now part of the public record.

The content enclosed in Item 2.02 of the Form 8-K relates to the declaration of the company’s financial status and should be noted as having been communicated to the Securities and Exchange Commission for regulatory purposes. It is essential to underscore that the data shared within this section is being presented solely for informational purposes and is not to be regarded as formally filed under Section 18 of the Securities Exchange Act of 1934. Additionally, it should not be construed as integrated by reference in any forthcoming submissions under the Securities Act of 1933 or the Exchange Act, unless explicitly indicated by particular reference in such filings.

Furthermore, under Item 9.01 of the report, various exhibits have been outlined, with Exhibit 99.1 being specifically highlighted as the disclosure containing Teva’s 2024 Full Year and Fourth Quarter Financial Results. In addition, an Interactive Data File incorporated within the Inline XBRL document has been cited in Exhibit 104.

In closing, the regulatory obligations as stipulated by the Securities Exchange Act of 1934 have been met through the due authorization and signature affixed on behalf of Teva Pharmaceutical Industries Limited. The signatory on the report confirmed on January 29, 2025, is Eli Kalif, serving in the capacity of Executive Vice President and Chief Financial Officer for the organization.

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Teva Pharmaceutical Industries’s 8K filing here.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.